Member Info for Saxondale

Apologies again - LOA up TO 40% .

Maybe I should read it a bit slower . I'd say LOA should be 100% to be honest - I mean they have an unmet medical need , Orphan drug status - Fast Track Designation , and a relatively small P3 to achieve approval , and currently are getting 80% response rates .

Apologies - LOA ( likely hood of approval ) up by 40%

However , I expect SP to surge on expectation of deal - regardless of conservative research note .

Yes thanks for that .

Some good weekend reading

Conservatively they say , even without a deal - a positive P2 readout would give a 40% upside .

Well ,we know that the readout will be positive - and we expect survival data to be getting better too .

Just a week or 2 now until that P2 readout .

An investment in Faron is inherently dependent on the outcome of the BEXMAB study. A

positive readout could lead us to raise our likelihood of approval (LOA), thereby reducing the

risk adjustment applied to our estimated cash flow streams. All else being equal, increasing the

LOA to 40% would raise our fair value range to EUR2.6–3.4 per share. Furthermore, positive

survival data could increase our fair value range even further, to EUR3.0–4.0 per share.

There have been patents filed previously regarding patient identification - but I think this recent one is a lot more concise and detailed - with all 4 biomarkers described - and so giving a more comprehensive overview of how well informed the doctors would be as to the suitability of a potential patient .

Https://patents.justia.com/patent/20250051438

Published Feb 13th 2025

Another patent that sets out how differently the patients can be selected compared to traditional checkpoint inhibitors - as for anti Clever 1 treatment - the total opposite of how the others do it ( In fact according to this - for them ,there is no clear biomarker guidance available to guide treatment ) .

This kind of selection criteria is a major bonus for Faron ,

From the blurb

Currently, immune checkpoint inhibitors targeting CTLA-4 and the PD-1/PD-L1 axis are approved for clinical use, and while highly efficacious in about 10-20% of patients with melanoma and certain other tumors, several other important cancer types (such as prostate, breast and colorectal cancer) remain refractory to them, and there is no clear biomarker available that could differentiate responders from non-responders and guide treatment

83% of patients who have low levels of IFNg and TNF-α are expected to experience clinical benefit when treated with anti-CLEVER-1 antibody bexmarilimab. Further, the likelihood of predicting response to anti-CLEVER-1 antibody bexmarilimab increases to 91%, if classical pro-inflammatory cytokines such as interleukin 6 (IL-6) and/or interleukin 8 (IL-8) are added to the ROC analyses. Also, it has been observed that a standard inflammatory laboratory value C-reactive protein (CRP) has excellent ability to reflect a non-inflammatory cancer type, that is responsive to anti-CLEVER-1 antibody bexmarilimab.

A method for choosing a patient to anti-CLEVER-1 therapy prior to beginning anti-CLEVER-1 therapy using one or several of the inflammatory markers selected from interferon gamma (IFNγ), tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6), interleukin 8 (IL-8) and C-reactive protein. When the measured level of the inflammatory marker is substantially within the reference values of the inflammatory marker or lower than the average reference value of the inflammatory marker, it is an indication to choose the patient and begin the anti-CLEVER-1 therapy.

Now up nearly 9% @ 2.5 euro .

Usually AGMs are a non event . Perhaps this one may be a bit fruity ?

Bit of a surge on Naz - up 6.75% 2.45 euro .

Can only buy 1000 shares at a time on LSE @ 190.00 ( I had two top ups )

Could be a shrewd move to keep their options open . It would be bad to finish P2 with no other option than a BP deal . This way they can perhaps show that it is possible to go it alone . Either way , this chap looks to have good expertise in whats coming next .

Great stuff . All positive from FDA . Bodes well for the future , they are being given every helping hand along the way to get Bex on the market ASAP , helping patients and rewarding investors

Had a quick scan of this Rns , usual proposals as we’ve seen before . Good to see BOD members such as Roth etc sticking , and interested to see amendment relating to takeover rules . Just in case we are taken over I guess .

Been a bit busy of late , not delved into it . If you’ve been a holder of other shares such as AvCT you could spend half of your day chasing down rabbit holes and such like . A few weeks now Until theP2 readout , should be good reading .

I couldn’t resist a top up yesterday too . Something regarding sale/ deal / partnering bidding could drop anytime now onwards , we may not get much warning . It may not have to wait for the April readout or fda meeting .

Good strategic move . Clear intent shown

In the old days the SP valuations were finger in the air predictions .

Now thanks to much analysis - by Faron / analysts and investors - it is very much based on fact .

Not long to wait hopefully

Looks like the update is pretty much just an adjustment due to share dilution (2.8 - 2.5 base case)

But they conclude that Faron is now in a much better position to hit milestones and increase shareholder value

Ultimately, we argue that this private placement underscores investor confidence in Faron’s prospects and the potential of bexmarilimab. With its financial position now significantly strengthened, the company can focus on executing its clinical and regulatory strategy, advancing bexmarilimab toward late-stage development, and securing a meaningful commercial partnership that could unlock further value for shareholders.

Mcap is still just about £200m

The Redeye analysis had the business worth billions - with approval .

80% response rate - P2 just finishing up .

Every box is ticked - apart from who is buying it .

It's coming up to a couple of years ago when a certain Southampton based company dropped a complete bomb of an RNS with a failed P3 trial result . I don't think I'll ever risk so much on a blind trial result again . Lesson learnt - and luckily I survived and moved on - and am still a believer that projects can come good and deliver outstanding for investors .

Faron have over the last year delivered on all fronts that you could ask for in building the platform .

The risk here on is very marginal . We are talking asteroid strike % s.

Bex will be on the market - thats for sure . Its all the extra parts that are exciting - potentially years of new discoveries around the combination studies on solid tumours etc .

I count Faron and AVCT in the same style of exciting future .

Both shares have had to endure some financial headaches - but both are now coming out of the 'nuclear winter' and bar that asteroid - investors should do very well .

I see Timo has moved from Switzerland to Monaco .

Planning ahead perhaps , because when Faron hit the jackpot , he's gonna need somewhere pretty flash to park his super-yacht.

His holding at present is worth about £30 million . Imagine a 10 bagger ( fairly reasonable assumption now ) . I bet he's flicking through the Gulfstream catalogue as well lol ( if he hasn't already got one )

Currently

£1.75-£1.80 on LSE

8,853000 vol on Naz at 2.16 euro

Juho-

'Geared for Success'

80% response rate

April readout

A lot of business stuff happening in 2025